60 Degrees Pharmaceuticals (SXTP)
Develops and markets tafenoquine medicines for malaria prevention and vector-borne diseases.
60 Degrees Pharmaceuticals Announces Second Quarter 2026 Results
WASHINGTON, Aug. 14, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the “Company”), a pharmaceutical company focused on developing new medicines for vector-borne diseases, reported today its financial results for the second quarter of 2026, ended June 30, 2026. Financial Highlights for the Quarter Ended June 30, 2026: Net product revenues increased approximately 106% to approximately $208 thousand for the second quarter of 2026, from approximately $101 thousand for the second quarter of 2025.
60 Degrees Pharmaceuticals Announces Minimum Enrollment Achieved in Hospitalized Babesiosis Study; Interim Data Readout Planned by October 6, 2026
Company plans to request an FDA meeting following the interim readout to discuss the regulatory pathway for a New Drug Application (NDA) for tafenoquine in babesiosis WASHINGTON, July 29, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60 Degrees” or the “Company”), a pharmaceutical company that develops and commercializes new medicines for vector-borne disease, today announced it has enrolled the minimum 24 patients needed to trigger an interim analysis in its clinical study of patients hospitalized with severe babesiosis ( NCT06207370 ). The outcome of the interim analysis will be disclosed no later than October 6, 2026.
60 Degrees Pharmaceuticals Announces Exclusive Option Agreement with Florida State University to Advance Castanospermine for Tick-Borne Diseases
60 Degrees Pharma (Nasdaq: SXTP) secures exclusive option to develop castanospermine for tick-borne diseases, expanding its infectious disease pipeline.
60 Degrees Pharmaceuticals Announces Positive Recommendation from Data Safety Monitoring Board for B-FREE Phase 2 Study of Tafenoquine for Treatment of Chronic Babesiosis Patients with Severe Fatigue
WASHINGTON, July 01, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60 Degrees Pharma” or the “Company”), a pharmaceutical company focused on developing new medicines for vector-borne disease, announced today that the independent Data Safety Monitoring Board has recommended continuation of the B-Free chronic babesiosis study ( NCT06656351 ), following a review of safety data from the first six patients from baseline through Day 30. The B-Free study is evaluating recovery from fatigue following treatment with the ARAKODA® regimen of tafenoquine (loading dose of 200 mg per day for four days, then 200 mg weekly through Day 90) in patients with severe persistent fatigue and laboratory evidence of exposure to Babesia spp.
60 Degrees Pharmaceuticals Signs Exclusive Patent License Agreement with Florida State University for Non-Prescription Use of Australian Chestnut Extract as a Botanical Supplement
License allows the Company to commence large-scale extraction of castanospermine from the seeds of Castanospermum australe Company will meet with FDA on July 1, 2026, to discuss Non-Notified Letter issued by the Agency in response to the Company's recent New Dietary Ingredient Notification (NDIN) to market Australian Chestnut Extract in the U.S. WASHINGTON, June 11, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the “Company” or “60 Degrees Pharma”), a pharmaceutical company focused on developing new medicines for vector-borne disease, announced that the Company has executed a patent licensing agreement with Florida State University to commence large-scale production techniques to extract and purify castanospermine from the seeds of Castanospermum australe (commonly known as the Australian Chestnut, the Moreton Bay Chestnut, and the Black Bean Tree) for non-prescription uses. Castanospermine is the principal component of Australian Chestnut Extract.
60 Degrees Pharmaceuticals Announces Early Enrollment of First Seasonal Patient in Clinical Trial of Tafenoquine for Patients Hospitalized with Babesiosis
Enrollment is tracking ahead of schedule, allowing potential acceleration of key trial milestones Minimum enrollment to support interim analysis expected as soon as early July 2026 Randomized, double-blind, placebo-controlled trial is evaluating the efficacy and safety of tafenoquine in treating humans hospitalized with babesiosis at five clinical sites in northeastern U.S. WASHINGTON, May 26, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the “Company” or 60 Degrees Pharmaceuticals), a pharmaceutical company focused on developing new medicines for vector-borne disease, announced that the first patient of the 2026 tick season has been enrolled in the randomized, double-blind, placebo-controlled clinical trial ( NCT06207370 ) to evaluate the efficacy and safety of tafenoquine in treating babesiosis in humans. The study, which will enroll at least 24 patients prior to an interim analysis, is being conducted at five clinical sites in the Northeastern United States.
60 Degrees Pharmaceuticals Announces First Quarter 2026 Results
WASHINGTON, May 15, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP ; SXTPW) (the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, today reported its financial results for the first quarter of fiscal year 2026, ended March 31, 2026. Financial Highlights for the Quarter Ended March 31, 2026: Net product revenues decreased approximately 1% from $164 thousand for the first quarter of 2025 to approximately $162 thousand for the first quarter of 2026.
60 Degrees Pharmaceuticals Inc. (NASDAQ:SXTP) Sees Significant Decline in Short Interest
60 Degrees Pharmaceuticals Inc. (NASDAQ: SXTP - Get Free Report) was the target of a significant decline in short interest during the month of March. As of March 31st, there was short interest totaling 160,681 shares, a decline of 66.9% from the March 15th total of 484,774 shares. Based on an average daily volume of 371,994
60 Degrees Pharmaceuticals Inc. (SXTP) Upgraded to Buy: Here's What You Should Know
60 Degrees Pharmaceuticals Inc. (SXTP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
60 Degrees Pharmaceuticals Announces 2025 Annual Results
FY 2025 net product revenues increased 65% to $1,005,000 Current shelf capacity exhausted after raise of $4 million through an ATM facility WASHINGTON, March 31, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the “Company”), a pharmaceutical company focused on developing new medicines for vector-borne disease, reported today its financial results for the 2025 fiscal year ended December 31, 2025. Financial Highlights for the Fiscal Year Ended December 31, 2025: Net product revenues increased 65% from $607.6 thousand in 2024 to $1.0 million in 2025, driven by rising sales, price increases, and fewer returns.
60 Degrees Pharmaceuticals Files New Dietary Ingredient Notification (NDIN) with FDA for Australian Chestnut Extract
60 Degrees files NDIN with FDA for Australian Chestnut Extract; May 25 decision deadline. FSU capsule license option expands commercialization strategy.
What's Going On With 60 Degrees Pharmaceuticals On Friday?
60 Degrees Pharmaceuticals Inc. (NASDAQ: SXTP) shares are down during Friday's premarket session. This follows a 9.6% decline, closing at $2.91 on Thursday.
60 Degrees Pharmaceuticals Announces All Patients Cured of Babesiosis After Tafenoquine Treatment in Expanded Use Clinical Trial
All three patients in 60 Degrees Pharma's expanded access study were cured of relapsing babesiosis after tafenoquine treatment, supporting guideline review
60 Degrees Pharmaceuticals (NASDAQ:SXTP) Shares to Reverse Split on Tuesday, January 20th
60 Degrees Pharmaceuticals Inc. (NASDAQ: SXTP) shares are set to reverse split on the morning of Tuesday, January 20th. The 1-4 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the closing bell on Monday, January 19th. 60 Degrees Pharmaceuticals Trading Down 2.4% SXTP stock opened
60 Degrees Pharmaceuticals Announces Detection of Babesia Infection in 24 Percent of Patients Presenting with Chronic Fatigue in Peer-Reviewed, Sponsored Study at NC State
Peer-reviewed NC State study found Babesia in 24% of chronic fatigue patients, supporting further study of chronic babesiosis and ARAKODA® evaluation.
Here's Why 60 Degrees Pharmaceuticals Inc. (SXTP) Looks Ripe for Bottom Fishing
60 Degrees Pharmaceuticals Inc. (SXTP) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
60 Degrees Pharmaceuticals Announces Expansion of ARAKODA® Sales and Marketing in 2026
60 Degrees Pharmaceuticals will expand ARAKODA sales in 2026 with more reps, a GoodRx partnership, enhanced digital marketing, and added babesiosis trials
60 Degrees Pharmaceuticals Announces Clinical Site Now Open for Patient Enrollment for the B-FREE Chronic Babesiosis Study at Mount Sinai Icahn School of Medicine
60 Degrees Pharma opens enrollment at Mount Sinai for its B-FREE trial testing tafenoquine in chronic babesiosis, addressing a major unmet medical need.
60 Degrees Pharmaceuticals Announces Third Quarter 2025 Results
60 Degrees Pharma reports 223% YoY revenue growth in Q3 2025; advances babesiosis programs with Tulane, Mount Sinai, and MUMS canine designation plans.
60 Degrees Pharmaceuticals Announces No Detection of Babesia Infection in First Patient Following Treatment with Tafenoquine in Relapsing Babesiosis Study
Breakthrough Therapy Designation request has been submitted to FDA Company to request a Type B meeting with FDA in early 2026 to discuss requirements for a supplementary New Drug Application (sNDA) Results obtained using highest sensitivity test available; licensed by FDA for blood donation screening Remaining enrolled patients will complete the study between January and October 2026 Study intended to confirm the high cure rate for tafenoquine in immunosuppressed patients with relapsing babesiosis, as reported by Yale in a 2024 publication WASHINGTON, Oct. 15, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60 Degrees” or the “Company”), a pharmaceutical company focused on developing new medicines for vector-borne disease, today announced that the first patient to have completed the regimen in the Company's trial of relapsing babesiosis in immunosuppressed patients has tested negative for babesiosis. The trial is an expanded access study of ARAKODA® (tafenoquine) in combination with conventional treatments for relapsing babesiosis ( NCT06478641 ).